Shares of Ipsen S.A. (EPA:IPN) tumbled 7.31% on Monday, closing at €144.50 by 11:13 CEST, after Amneal Pharmaceuticals (NASDAQ:AMRX) received U.S. FDA approval and immediately launched a generic version of Somatuline Depot, Ipsen's flagship oncological treatment.
The approval, granted on September 21, 2026, covers a 120 mg prefilled syringe of lanreotide injection, a formulation that directly competes with Somatuline at its highest prescribed strength. Amneal secured competitive generic therapy (CGT) designation, which accelerates regulatory review when few alternatives exist, underscoring the strategic importance of this launch.
For Ipsen, the timing is critical. Somatuline generated €686.3 million in first-half 2026 sales, a 16.6% increase year-over-year, but that growth was partly attributed to supply constraints faced by generic competitors in North America and Europe. With Amneal now entering the market, that advantage evaporates, and the company faces real price and volume pressure.
The market reaction was swift: Ipsen's equity value fell by approximately €955 million, based on 83.81 million shares outstanding. The stock opened at €151.00 and traded in a range of €143.70 to €151.10, with volume reaching 70,740 shares—85% of the daily average. The selloff reflects investor concern that the generic threat, previously seen as a distant risk, is now commercial reality.
Amneal's launch targets the U.S. market, where brand sales for Somatuline reached $983 million through July 2026. While the company did not disclose pricing, the entry of a generic typically leads to significant discounting and market share erosion. Analysts had already been divided on Ipsen's outlook prior to this news. AlphaValue raised its price target to €204 on Friday, citing the strength of Ipsen's pipeline, while Barclays downgraded the stock to Underweight with a €155 target earlier this month, anticipating exactly this kind of competitive pressure.
Ipsen's management has emphasized diversification. In the first half, sales from products other than Somatuline grew 24.8% at constant currencies, and the company ended June with €1.005 billion in net cash. CEO David Loew highlighted the accelerating portfolio beyond Somatuline, but Monday's selloff suggests investors believe the company will need more than pipeline promise to offset the impact on its top-selling drug.
At the current price, Ipsen trades at 9.8 times 2026 earnings and 10.6 times 2027 earnings, with EPS expected to decline 7.3% next year. The market is clearly pricing in a significant hit to Somatuline's U.S. franchise. However, Amneal has only launched the 120 mg strength, and Somatuline is sold in many other markets globally, which could mitigate the damage.
The next key test will be Ipsen's third-quarter sales report, scheduled for October 22, 2026. Investors will scrutinize North American Somatuline performance against the company's guidance for over 20% sales growth and a core operating margin above 37%. If the generic uptake is slower than feared, Monday's €955 million loss may prove excessive; conversely, aggressive discounting could force Ipsen to revise its outlook.
